C12Y 207/12002
Mitogen-activated protein kinase kinase , i.e. mapkk or mek1 or mek2
Official title: Mitogen-activated protein kinase kinase (2.7.12.2), i.e. MAPKK or MEK1 or MEK2
C12Y207/12002 (Mitogen-activated protein kinase kinase , i.e. mapkk or mek1 or mek2) appears on 17 US grants and 27 published applications in this corpus.
Search patents in C12Y- Granted patents
- 17
- Published applications
- 27
- Assignees
- 19
- Inventors
- 74
- Latest grant
- 28 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 0 | 3 |
| 2015 | 2 | 0 |
| 2016 | 1 | 4 |
| 2017 | 2 | 2 |
| 2018 | 1 | 4 |
| 2019 | 2 | 1 |
| 2020 | 3 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 1 | 1 |
| 2024 | 0 | 3 |
| 2025 | 1 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Activating mitotic checkpoint control mechanisms28 Oct 2025US 12,454,559 B2The Regents of the University of Michigan
- MEK1 mutation conferring resistance to RAF and MEK inhibitors17 Oct 2023US 11,789,022 B2Dana-Farber Cancer Institute, Inc.
- Synergistic cancer treatment6 Oct 2020US 10,792,284 B2Memorial Sloan Kettering Cancer Center
- MEK1 mutation conferring resistance to RAF and MEK inhibitors29 Sep 2020US 10,788,496 B2Dana-Farber Cancer Institute, Inc.
- Mps1 and KNL1 phosphorylation system2 Jun 2020US 10,669,320 B2The Regents of the University of Michigan
- Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use6 Mar 2025US 2025/0073333 A1Board of Regents, The University of Texas System
- Compositions and methods for treating osteoarthritis using a cd14 inhibitor18 Jul 2024US 2024/0239913 A1
- MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors21 Mar 2024US 2024/0094208 A1Dana-Farber Cancer Institute, Inc.
- Activating mitotic checkpoint control mechanisms8 Feb 2024US 2024/0043480 A1The Regents of the University of Michigan
- Recombinant proteins for quantification of protein levels17 Aug 2023US 2023/0257430 A1Genentech, Inc.
Most cited
By later US patents
- Antisense inhibition of MAP kinase kinase 6 expression71US 6,033,910 AIsis Pharmaceuticals, Inc. · 2000
- MEK ligands and polynucleotides encoding MEK ligands5US 8,575,304 B2Intrexon Corporation · 2013
- Mitogen activated protein kinase (MAPK) kinase3US 6,465,618 B1Asahi Kasei Kabushikiki Kaisha · 2002
- Methods and compositions for reducing blood glucose1US 9,186,393 B2Children's Medical Center Corporation · 2015
- Method for reducing blood glucose1US 9,730,985 B2Children's Medical Center Corporation · 2017